Healthcare sub-sectors breakdown
Healthcare is four different industries sharing one sector label, pharma, devices, payers, and providers, each with its own economics and its own valuation method, and refusing to blend them is the whole discipline.
"Healthcare" is four different industries sharing one sector label, each with its own economics: drugmakers, device makers, insurers/payers, and care providers. Analyzing it means refusing the blend (the conglomerate lesson at sector scale), and the era's defining question, whether GLP-1 drugs reshape the entire category, cuts across all four. This guide frames the sector professionally.
Four sectors wearing one label
| Sub-sector | Economics | How it's valued |
|---|---|---|
| Pharma / biotech | Patent monopolies with fat margins that expire on a known date | DCF around the patent cliff; pipeline as option value |
| Medical devices | Razor-and-blade: installed base + recurring consumables; high switching costs | Quality-compounder multiples; moats measurable |
| Payers / insurers | Premiums minus medical costs (the medical loss ratio): a spread business | Like financials: book, ROE, the Other Intrinsic Methods insurer tools |
| Providers / services | Hospitals, labs, distributors: thin margins, high volume, policy-exposed | Operating leverage and reimbursement; often the cyclical/regulated end |
The demographic tailwind, and why defensive
Two structural facts underwrite the sector. First, aging: the 65+ population is growing across the developed world and consumes several times the healthcare of younger cohorts, a decades-long demand ramp visible in census data, not a forecast. Second, inelasticity: people do not defer necessary care in a recession the way they defer a car, which gives healthcare equities their defensive character (earnings that hold up when the cycle turns). That defensiveness is why the sector often leads late-cycle and lags in risk-on rallies, a rotation the macro guide's cycle table anticipates.
The pharma engine and the patent cliff
A branded drug is a temporary legal monopoly: patent protection allows high prices and enormous margins for a fixed period, after which generics enter and revenue can fall 80-90% within a year or two. This makes pharma valuation a specialized DCF: model each major drug's cash flows to its patent expiry, then collapse, and value the PIPELINE separately as a portfolio of options (each candidate a probability-weighted payoff, since clinical trials are binary events). A big-pharma thesis is really two questions: how large is the cliff over the next five years, and can the pipeline (internal plus acquisitions) refill the hole? Companies staring at a major cliff trade cheap FOR A REASON, exactly the cheap-versus-undervalued distinction: the discount is the market pricing the coming revenue loss, and the thesis is whether the refill is underestimated.
The GLP-1 disruption
GLP-1 agonists (originally diabetes drugs, now blockbuster weight-loss treatments) are the sector's live disruption and a case study in second-order analysis. First-order: an enormous new drug market accruing to a few makers. Second-order, and where the analysis gets interesting: if a large share of the population loses significant weight, DEMAND shifts across the whole economy: less need for some diabetes and cardiac devices, changed demand for dialysis, sleep-apnea equipment, even packaged food and restaurants. Analysts had to redraw demand curves for companies that never made a GLP-1, which is the AI-thesis's second-order logic in a different sector: the biggest effects of a breakthrough often land on companies adjacent to it, and mapping those ripples is where non-consensus views live.
The sector's permanent risks
- Patent cliffs: known in timing, brutal in magnitude; the single biggest pharma-specific risk.
- Binary clinical trials: a phase-3 failure can erase years of value overnight; pipeline value is option value, and options expire worthless routinely. Position sizing must respect the binary.
- Policy and pricing. Drug-pricing reform, reimbursement decisions, and formulary changes can reset a business model by legislation. The sector trades on political headlines more than most, and policy risk resists modeling: it is a fat-tailed, hard-to-hedge exposure.
- Litigation: product liability and opioid-style settlements can be existential, and they surface in footnotes years after the products shipped (the statements-guide red flag).
- The payer squeeze: insurers and pharmacy-benefit managers sit between drugmakers and patients, and their negotiating power caps realized prices below list.
What professionals watch
- The patent-cliff calendar for each major pharma: revenue at risk by year, against pipeline read-outs and M&A capacity.
- Clinical-trial catalysts: phase-3 read-outs and FDA decisions are dated, binary, and often the whole thesis (the catalyst discipline from the thesis guide).
- GLP-1 penetration and its ripples: uptake curves, supply constraints, and the demand redraw across adjacent industries.
- Policy signals: drug-pricing legislation, reimbursement rulings, and reform proposals: the sector's fat tail.
- Device installed-base and utilization: the razor-and-blade recurring-revenue health, and elective-procedure volumes for the cyclical read.
- Moat
- A structural barrier that stops a company's high returns from being competed away: network effects, switching costs, brands and patents, cost advantage, or efficient scale. The durable question is never whether a business is profitable but what protects the profits.
- Switching costs
- The money, time and risk a customer would incur to leave. High switching costs show up in the numbers as retention; the claim without the retention is just hope.
- Terminal value
- The value of all cash flows beyond the explicit forecast, collapsed into a single number at the forecast's end. It routinely carries more than half of a DCF's total value, which is why its assumptions deserve the most scrutiny.
- Reverse DCF
- Running the machine backwards: instead of estimating value from assumptions, solve for the growth and margins the current price already implies, then judge whether those are beatable. Often more honest than the forward version, because it removes your favorite input.
- Combined ratio
- An insurer's claims plus expenses divided by premiums earned. Under 100% means the underwriting itself is profitable before any investment income; over it means the insurer pays for the float it invests.
- Book value
- Shareholders' equity as the balance sheet states it: assets minus liabilities. Meaningful where assets are financial or tangible (banks, insurers), nearly meaningless where the real assets are brands and code.
- Catalyst
- The event expected to force the market to reprice toward your view: earnings, a spin-off, a regulatory decision, a contract. Cheap without a catalyst can stay cheap for years; the catalyst is the thesis's clock.
- Falsifier
- The observable fact, chosen in advance, that would prove the thesis wrong and trigger exit. Deciding it while calm is cheap; deciding it mid-drawdown is expensive, which is why professionals write it down first.
- Expected value
- The probability-weighted average of the outcomes: bull, base and bear prices times their odds. The number that decides whether a position is attractive, and the reason a likely-wrong idea with a huge payoff can beat a likely-right one with none.
- Footnotes
- The notes attached to audited financial statements: debt maturities, leases, segments, pensions, litigation, accounting policies. The fine print that professionals read first, because it is where inconvenient detail is required to live.